1
|
Leu CL, Lam DD, Salminen AV, Wefers B, Becker L, Garrett L, Rozman J, Wurst W, de Angelis MH, Hölter SM, Winkelmann J, Williams RH. A patient-enriched MEIS1 coding variant causes a restless legs syndrome-like phenotype in mice. Sleep 2024:zsae015. [PMID: 38314840 DOI: 10.1093/sleep/zsae015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2023] [Indexed: 02/07/2024] Open
Abstract
Restless legs syndrome (RLS) is a neurological disorder characterized by uncomfortable or unpleasant sensations in the legs during rest periods. To relieve these sensations, patients move their legs, causing sleep disruption. While the pathogenesis of RLS has yet to be resolved, there is a strong genetic association to the MEIS1 gene. A missense variant in MEIS1 is enriched 7-fold in RLS patients compared to non-affected individuals. We generated a mouse line carrying this mutation (p.Arg272His/c.815G>A), referred to herein as Meis1R272H/R272H (Meis1 point mutation), to determine whether it would phenotypically resemble RLS. As women are more prone to RLS, driven partly by an increased risk of developing RLS during pregnancy, we focussed on female homozygous mice. We evaluated RLS-related outcomes, particularly sensorimotor behavior and sleep, in young and aged mice. Compared to non-carrier littermates, homozygous mice displayed very few differences. Significant hyperactivity occurred before the lights-on (rest) period in aged female mice, reflecting the age-dependent incidence of RLS. Sensory experiments involving tactile feedback (rotorod, wheel running, and hotplate) were only marginally different. Overall, RLS-like phenomena were not recapitulated except for the increased wake activity prior to rest. This is likely due to the focus on young mice. Nevertheless, the Meis1R272H mouse line is a potentially useful RLS model, carrying a clinically relevant variant and showing an age-dependent phenotype.
Collapse
Affiliation(s)
- Chia-Luen Leu
- Institute of Neurogenomics, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany
| | - Daniel D Lam
- Institute of Neurogenomics, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany
- Institute of Human Genetics, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Germany
| | - Aaro V Salminen
- Institute of Neurogenomics, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany
- Institute of Human Genetics, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Germany
| | - Benedikt Wefers
- Institute of Developmental Genetics, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany
| | - Lore Becker
- Institute of Experimental Genetics, German Mouse Clinic, Helmholtz Center Munich, Neuherberg, Germany
| | - Lillian Garrett
- Institute of Developmental Genetics, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany
- Institute of Experimental Genetics, German Mouse Clinic, Helmholtz Center Munich, Neuherberg, Germany
| | - Jan Rozman
- Institute of Experimental Genetics, German Mouse Clinic, Helmholtz Center Munich, Neuherberg, Germany
- German Center for Diabetes Research (DZD), Neuherberg
- Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 6, avenue du Swing, 4367, Belvaux, Luxembourg
| | - Wolfgang Wurst
- Institute of Developmental Genetics, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany
- German Center for Neurodegenerative Diseases (DZNE), Site Munich, Germany
- Chair of Developmental Genetics, TUM School of Life Sciences, Technische Universität München, Freising, Germany
- Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
| | - Martin Hrabě de Angelis
- Institute of Experimental Genetics, German Mouse Clinic, Helmholtz Center Munich, Neuherberg, Germany
- Chair of Experimental Genetics, TUM School of Life Sciences, Technische Universität, München, Freising, Germany
- German Center for Diabetes Research (DZD), Neuherberg
| | - Sabine M Hölter
- Institute of Developmental Genetics, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany
| | - Juliane Winkelmann
- Institute of Neurogenomics, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany
- Institute of Human Genetics, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Germany
- Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
| | - Rhîannan H Williams
- Institute of Neurogenomics, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany
| |
Collapse
|
2
|
Schormair B, Zhao C, Salminen AV, Oexle K, Winkelmann J. Reassessment of candidate gene studies for idiopathic restless legs syndrome in a large genome-wide association study dataset of European ancestry. Sleep 2022; 45:6576194. [PMID: 35486972 PMCID: PMC9366638 DOI: 10.1093/sleep/zsac098] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Revised: 04/06/2022] [Indexed: 11/12/2022] Open
Abstract
Abstract
Study Objectives
Several candidate gene studies have been published for idiopathic restless legs syndrome (RLS) in populations of European ancestry, but the reported associations have not been confirmed in independent samples. Our aim was to reassess these findings in a large case–control dataset in order to evaluate their validity.
Methods
We screened PubMed for RLS candidate gene studies. We used the genome-wide association study (GWAS) dataset of the International EU-RLS-GENE Consortium as our replication sample, which provided genome-wide single-variant association data based on at most 17 220 individuals of European ancestry. We performed additional gene-based tests using the software MAGMA and assessed the power of our study using the genpwr R package.
Results
We identified 14 studies conducted in European samples which assessed 45 variants in 27 genes of which 5 variants had been reported as significantly associated. None of these individual variants were replicated in our GWAS-based reassessment (nominal p > 0.05) and gene-based tests for the respective five genes ADH1B, GABRR3, HMOX1, MAOA, and VDR, were also nonsignificant (nominal p > 0.05). Our replication dataset was well powered to detect the reported effects, even when adjusting for effect size overestimation due to winner’s curse. Power estimates were close to 100% for all variants.
Conclusion
In summary, none of the significant single-variant associations from candidate gene studies were confirmed in our GWAS dataset. Therefore, these associations were likely false positive. Our observations emphasize the need for large sample sizes and stringent significance thresholds in future association studies for RLS.
Collapse
Affiliation(s)
- Barbara Schormair
- Institute of Neurogenomics, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH) , Neuherberg , Germany
- Institute of Human Genetics, School of Medicine, Technical University of Munich , Munich , Germany
| | - Chen Zhao
- Institute of Neurogenomics, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH) , Neuherberg , Germany
| | - Aaro V Salminen
- Institute of Neurogenomics, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH) , Neuherberg , Germany
| | - Konrad Oexle
- Institute of Neurogenomics, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH) , Neuherberg , Germany
- Institute of Human Genetics, School of Medicine, Technical University of Munich , Munich , Germany
| | - Juliane Winkelmann
- Institute of Neurogenomics, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH) , Neuherberg , Germany
- Institute of Human Genetics, School of Medicine, Technical University of Munich , Munich , Germany
- Chair of Neurogenetics, School of Medicine, Technical University of Munich , Munich , Germany
- Munich Cluster for Systems Neurology (SyNergy) , Munich , Germany
| | | |
Collapse
|
3
|
Salminen AV, Clemens S, García-Borreguero D, Ghorayeb I, Li Y, Manconi M, Ondo W, Rye D, Siegel JM, Silvani A, Winkelman JW, Allen RP, Ferré S. Consensus guidelines on the construct validity of rodent models of restless legs syndrome. Dis Model Mech 2022; 15:dmm049615. [PMID: 35946581 PMCID: PMC9393041 DOI: 10.1242/dmm.049615] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Accepted: 07/10/2022] [Indexed: 12/16/2022] Open
Abstract
Our understanding of the causes and natural course of restless legs syndrome (RLS) is incomplete. The lack of objective diagnostic biomarkers remains a challenge for clinical research and for the development of valid animal models. As a task force of preclinical and clinical scientists, we have previously defined face validity parameters for rodent models of RLS. In this article, we establish new guidelines for the construct validity of RLS rodent models. To do so, we first determined and agreed on the risk, and triggering factors and pathophysiological mechanisms that influence RLS expressivity. We then selected 20 items considered to have sufficient support in the literature, which we grouped by sex and genetic factors, iron-related mechanisms, electrophysiological mechanisms, dopaminergic mechanisms, exposure to medications active in the central nervous system, and others. These factors and biological mechanisms were then translated into rodent bioequivalents deemed to be most appropriate for a rodent model of RLS. We also identified parameters by which to assess and quantify these bioequivalents. Investigating these factors, both individually and in combination, will help to identify their specific roles in the expression of rodent RLS-like phenotypes, which should provide significant translational implications for the diagnosis and treatment of RLS.
Collapse
Affiliation(s)
- Aaro V. Salminen
- Institute of Neurogenomics, Helmholtz Zentrum München GmbH - German Research Center for Environmental Health, 85764 Neuherberg, Germany
- Institute of Human Genetics, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany
| | - Stefan Clemens
- Department of Physiology, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA
| | | | - Imad Ghorayeb
- Département de Neurophysiologie Clinique, Pôle Neurosciences Cliniques, CHU de Bordeaux, 33076 Bordeaux, France
- Université de Bordeaux, Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, UMR 5287, 33076 Bordeaux, France
- CNRS, Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, UMR 5287, 33076 Bordeaux, France
| | - Yuqing Li
- Department of Neurology, Norman Fixel Institute for Neurological Diseases, College of Medicine, University of Florida, Gainesville, FL 32610, USA
| | - Mauro Manconi
- Sleep Medicine Unit, Regional Hospital of Lugano, Neurocenter of Southern Switzerland, 6900 Lugano, Switzerland
- Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland
- Department of Neurology, University Hospital Inselspital, 3010 Bern, Switzerland
| | - William Ondo
- Houston Methodist Hospital Neurological Institute, Weill Cornell Medical School, Houston, TX 77070, USA
| | - David Rye
- Department of Neurology, Emory University School of Medicine, Atlanta, GA 30322, USA
| | - Jerome M. Siegel
- Neuropsychiatric Institute and Brain Research Institute, University of California, Los Angeles, CA 90095, USA
- Neurobiology Research, Veterans Administration Greater Los Angeles Healthcare System, North Hills, CA 91343, USA
| | - Alessandro Silvani
- Department of Biomedical and Neuromotor Sciences Alma Mater Studiorum, Università di Bologna, 48121 Ravenna Campus, Ravenna, Italy
| | - John W. Winkelman
- Departments of Psychiatry and Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
| | - Richard P. Allen
- Department of Neurology, Johns Hopkins University, Baltimore, MD 21224, USA
| | - Sergi Ferré
- Integrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, USA
| | | |
Collapse
|
4
|
Salminen AV, Silvani A, Allen RP, Clemens S, Garcia-Borreguero D, Ghorayeb I, Ferré S, Li Y, Ondo W, Picchietti DL, Rye D, Siegel JM, Winkelman JW, Manconi M. Consensus Guidelines on Rodent Models of Restless Legs Syndrome. Mov Disord 2021; 36:558-569. [PMID: 33382140 PMCID: PMC8313425 DOI: 10.1002/mds.28401] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2020] [Revised: 09/29/2020] [Accepted: 10/26/2020] [Indexed: 01/18/2023] Open
Abstract
Restless legs syndrome (RLS) is a chronic sensorimotor disorder diagnosed by clinical symptoms. It is challenging to translate the diagnostic self-reported features of RLS to animals. To help researchers design their experiments, a task force was convened to develop consensus guidelines for experimental readouts in RLS animal models. The RLS clinical diagnostic criteria were used as a starting point. After soliciting additional important clinical features of RLS, a consensus set of methods and outcome measures intent on capturing these features-in the absence of a face-to-face interview-was generated and subsequently prioritized by the task force. These were, in turn, translated into corresponding methods and outcome measures for research on laboratory rats and mice and used to generate the final recommendations. The task force recommended activity monitoring and polysomnography as principal tools in assessing RLS-like behavior in rodents. Data derived from these methods were determined to be the preferred surrogate measures for the urge to move, the principal defining feature of RLS. The same tools may be used to objectively demonstrate sleep-state features highly associated with RLS, such as sleep disturbance and number and periodicity of limb movements. Pharmacological challenges and dietary or other manipulations that affect iron availability are desirable to aggravate or improve RLS-like behavior and lend greater confidence that the animal model being proffered replicates key clinical features of RLS. These guidelines provide the first consensus experimental framework for researchers to use when developing new rodent models of RLS. © 2020 International Parkinson and Movement Disorder Society.
Collapse
Affiliation(s)
- Aaro V. Salminen
- Institute of Neurogenomics, Helmholtz Zentrum München GmbH - German Research Center for Environmental Health, Neuherberg, Germany,Institute of Human Genetics, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Alessandro Silvani
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy
| | - Richard P. Allen
- Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA
| | - Stefan Clemens
- Department of Physiology, Brody School of Medicine, East Carolina University, Greenville, North Carolina, USA
| | | | - Imad Ghorayeb
- Département de Neurophysiologie Clinique, Pôle Neurosciences Cliniques, CHU de Bordeaux, Bordeaux, France,Université de Bordeaux, Institut de Neurosciences Cognitives et Intégratives d’Aquitaine, UMR 5287, Bordeaux, France,CNRS, Institut de Neurosciences Cognitives et Intégratives d’Aquitaine, UMR 5287, Bordeaux, France
| | - Sergi Ferré
- National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, Maryland, USA
| | - Yuqing Li
- Norman Fixel Institute for Neurological Diseases, Department of Neurology, College of Medicine, University of Florida, Gainesville, Florida, USA
| | - William Ondo
- Houston Methodist Hospital Neurological Institute, Weill Cornell Medical School, Houston, Texas, USA
| | - Daniel L. Picchietti
- University of Illinois School of Medicine, Carle Illinois College of Medicine and Carle Foundation Hospital, Urbana, Illinois, USA
| | - David Rye
- Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Jerome M. Siegel
- Neuropsychiatric Institute and Brain Research Institute, University of California, Los Angeles, Los Angeles, California, USA,Neurobiology Research, Veterans Administration Greater Los Angeles Healthcare System, North Hills, California, USA
| | - John W. Winkelman
- Departments of Psychiatry and Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Mauro Manconi
- Sleep Medicine Unit, Regional Hospital of Lugano, Neurocenter of Southern Switzerland, Lugano, Switzerland,Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland,Department of Neurology, University Hospital Inselspital, Bern, Switzerland,Correspondence to: Dr. Mauro Manconi, Sleep Medicine, Neurocenter of Southern Switzerland, Via Tesserete 46, Regional Hospital of Lugano, 6900 Lugano, Switzerland;
| | | |
Collapse
|
5
|
Salminen AV, Schandra N, Schormair B, Oexle K, Winkelmann J. Therapeutic effectiveness of thalidomide in a patient with treatment-resistant restless legs syndrome. J Clin Sleep Med 2020; 16:1815-1817. [PMID: 32729462 DOI: 10.5664/jcsm.8696] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
None Recent developments in the genetics of restless legs syndrome (RLS) revealed associations of disease risk with genetic loci containing the genes coding cereblon, the protein bound by thalidomide, and its endogenous substrate MEIS2, whose degradation is inhibited by the thalidomide-cereblon interaction. Therefore it was hypothesized that thalidomide may be a potential treatment option for RLS. Here we report on the therapeutic effect of thalidomide in a patient with otherwise treatment-resistant RLS who received 100 mg thalidomide off-label for 3 weeks. The female patient, severely affected by RLS before treatment, experienced significant amelioration of the symptoms, increased self-reported sleep quality, and better daytime functioning during thalidomide treatment. This therapeutic success warrants larger studies investigating the efficacy of drugs of the thalidomide class in RLS.
Collapse
Affiliation(s)
- Aaro V Salminen
- Institute of Neurogenomics, Helmholtz Zentrum München GmbH - German Research Center for Environmental Health, Neuherberg, Germany.,Institute of Human Genetics, Technische Universität München, Munich, Germany.,Department of Neurology, Philipps-Universität Marburg, Marburg, Germany
| | - Nathalie Schandra
- Institute of Neurogenomics, Helmholtz Zentrum München GmbH - German Research Center for Environmental Health, Neuherberg, Germany.,Department of Neurology, Philipps-Universität Marburg, Marburg, Germany
| | - Barbara Schormair
- Institute of Neurogenomics, Helmholtz Zentrum München GmbH - German Research Center for Environmental Health, Neuherberg, Germany.,Institute of Human Genetics, Technische Universität München, Munich, Germany
| | - Konrad Oexle
- Institute of Neurogenomics, Helmholtz Zentrum München GmbH - German Research Center for Environmental Health, Neuherberg, Germany
| | - Juliane Winkelmann
- Institute of Neurogenomics, Helmholtz Zentrum München GmbH - German Research Center for Environmental Health, Neuherberg, Germany.,Institute of Human Genetics, Technische Universität München, Munich, Germany.,Chair of Neurogenetics, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.,Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
| |
Collapse
|
6
|
Tilch E, Schormair B, Zhao C, Salminen AV, Antic Nikolic A, Holzknecht E, Högl B, Poewe W, Bachmann CG, Paulus W, Trenkwalder C, Oertel WH, Hornyak M, Fietze I, Berger K, Lichtner P, Gieger C, Peters A, Müller‐Myhsok B, Hoischen A, Winkelmann J, Oexle K. Identification of Restless Legs Syndrome Genes by Mutational Load Analysis. Ann Neurol 2019; 87:184-193. [DOI: 10.1002/ana.25658] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2019] [Revised: 11/28/2019] [Accepted: 11/29/2019] [Indexed: 02/06/2023]
Affiliation(s)
- Erik Tilch
- Helmholtz Zentrum München GmbH, German Research Center for Environmental HealthInstitute of Neurogenomics Neuherberg Germany
| | - Barbara Schormair
- Helmholtz Zentrum München GmbH, German Research Center for Environmental HealthInstitute of Neurogenomics Neuherberg Germany
| | - Chen Zhao
- Helmholtz Zentrum München GmbH, German Research Center for Environmental HealthInstitute of Neurogenomics Neuherberg Germany
| | - Aaro V. Salminen
- Helmholtz Zentrum München GmbH, German Research Center for Environmental HealthInstitute of Neurogenomics Neuherberg Germany
| | - Ana Antic Nikolic
- Helmholtz Zentrum München GmbH, German Research Center for Environmental HealthInstitute of Neurogenomics Neuherberg Germany
| | - Evi Holzknecht
- Department of NeurologyMedical University of Innsbruck Innsbruck Austria
| | - Birgit Högl
- Department of NeurologyMedical University of Innsbruck Innsbruck Austria
| | - Werner Poewe
- Department of NeurologyMedical University of Innsbruck Innsbruck Austria
| | | | - Walter Paulus
- Department of Clinical NeurophysiologyUniversity Medical Center, Georg August University Göttingen Göttingen Germany
| | - Claudia Trenkwalder
- Clinic for NeurosurgeryUniversity Medical Center, Georg August University Göttingen Göttingen Germany
- Center of Parkinsonism and Movement DisordersParacelsus‐Elena Hospital Kassel Germany
| | - Wolfgang H. Oertel
- Helmholtz Zentrum München GmbH, German Research Center for Environmental HealthInstitute of Neurogenomics Neuherberg Germany
| | | | - Ingo Fietze
- Department of Cardiology and Angiology, Center of Sleep MedicineCharité‐Universitätsmedizin Berlin Berlin Germany
| | - Klaus Berger
- Institute of Epidemiology and Social MedicineUniversity of Münster Münster Germany
| | - Peter Lichtner
- Helmholtz Zentrum München GmbH, German Research Center for Environmental HealthInstitute of Human Genetics Neuherberg Germany
| | - Christian Gieger
- Helmholtz Zentrum München GmbH, German Research Center for Environmental HealthInstitute of Epidemiology II Neuherberg Germany
| | - Annette Peters
- Helmholtz Zentrum München GmbH, German Research Center for Environmental HealthInstitute of Epidemiology II Neuherberg Germany
| | - Bertram Müller‐Myhsok
- Munich Cluster for Systems Neurology Munich Germany
- Max Planck Institute of Psychiatry Munich Germany
- Institute of Translational MedicineUniversity of Liverpool Liverpool United Kingdom
| | - Alexander Hoischen
- Department of Human GeneticsRadboud University Medical Center Nijmegen The Netherlands
| | - Juliane Winkelmann
- Helmholtz Zentrum München GmbH, German Research Center for Environmental HealthInstitute of Neurogenomics Neuherberg Germany
- Munich Cluster for Systems Neurology Munich Germany
- Department of Neurogenetics and Institute of Human GeneticsTechnical University of Munich Munich Germany
| | - Konrad Oexle
- Helmholtz Zentrum München GmbH, German Research Center for Environmental HealthInstitute of Neurogenomics Neuherberg Germany
| |
Collapse
|
7
|
Salminen AV, Allen RP, Högl B, Inoue Y, Oertel W, Winkelman JW, Trenkwalder C, Sampaio C, Winkelmann J. Reply to: A note on rotigotine for restless legs syndrome after renal transplantation. Mov Disord 2019; 34:152-153. [PMID: 30653726 DOI: 10.1002/mds.27570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2018] [Accepted: 10/19/2018] [Indexed: 11/07/2022] Open
Affiliation(s)
- Aaro V Salminen
- Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany
| | - Richard P Allen
- Sleep Disorders Center, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States.,Department of Neurology, Johns Hopkins University, Baltimore, Maryland, United States
| | - Birgit Högl
- Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
| | - Yuichi Inoue
- Japan Somnology Center, Neuropsychiatric Research Institute, Tokyo, Japan.,Department of Somnology, Tokyo Medical University, Tokyo, Japan
| | - Wolfgang Oertel
- Department of Neurology, Philipps-Universität Marburg, Marburg, Germany
| | - John W Winkelman
- Harvard Medical School, Boston, Massachusetts, United States.,Departments of Psychiatry and Neurology, Massachusetts General Hospital, Boston, MA, United States
| | - Claudia Trenkwalder
- Department Neurosurgery, University Medical Center, Goettingen, Germany.,Paracelsus-Elena Hospital, Kassel, Germany
| | | | - Juliane Winkelmann
- Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany.,Chair Neurogenetics and Institute of Human Genetics, Technical University Munich, Germany.,Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
| |
Collapse
|
8
|
Salminen AV, Allen RP, Högl B, Inoue Y, Oertel W, Winkelman JW, Trenkwalder C, Sampaio C, Winkelmann J. Reply to: Safety of dopamine agonists for treating restless legs syndrome. Mov Disord 2019; 34:150-151. [PMID: 30653723 DOI: 10.1002/mds.27571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2018] [Accepted: 10/19/2018] [Indexed: 11/09/2022] Open
Affiliation(s)
- Aaro V Salminen
- Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany
| | - Richard P Allen
- Sleep Disorders Center, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States.,Department of Neurology, Johns Hopkins University, Baltimore, Maryland, United States
| | - Birgit Högl
- Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
| | - Yuichi Inoue
- Japan Somnology Center, Neuropsychiatric Research Institute, Tokyo, Japan.,Department of Somnology, Tokyo Medical University, Tokyo, Japan
| | - Wolfgang Oertel
- Department of Neurology, Philipps-Universität Marburg, Marburg, Germany
| | - John W Winkelman
- Harvard Medical School, Boston, Massachusetts, United States.,Departments of Psychiatry and Neurology, Massachusetts General Hospital, Boston, MA, United States
| | - Claudia Trenkwalder
- Department Neurosurgery, University Medical Center, Goettingen, Germany.,Paracelsus-Elena Hospital, Kassel, Germany
| | | | - Juliane Winkelmann
- Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany.,Chair Neurogenetics and Institute of Human Genetics, Technical University Munich, Germany.,Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
| |
Collapse
|
9
|
Winkelmann J, Allen RP, Högl B, Inoue Y, Oertel W, Salminen AV, Winkelman JW, Trenkwalder C, Sampaio C. Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)§. Mov Disord 2018; 33:1077-1091. [DOI: 10.1002/mds.27260] [Citation(s) in RCA: 113] [Impact Index Per Article: 18.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2016] [Revised: 10/25/2017] [Accepted: 10/27/2017] [Indexed: 12/30/2022] Open
Affiliation(s)
- Juliane Winkelmann
- Institute of Neurogenomics; Helmholtz Zentrum München; Munich Germany
- Department of Neurology and Department of Human Genetics; Klinikum rechts der Isar, Technical University; Munich Germany
- Munich Cluster for Systems Neurology (SyNergy); Munich Germany
| | - Richard P. Allen
- Sleep Disorders Center; Johns Hopkins Bayview Medical Center; Baltimore Maryland USA
- Department of Neurology; Johns Hopkins University; Baltimore Maryland USA
| | - Birgit Högl
- Department of Neurology; Medical University of Innsbruck; Innsbruck Austria
| | - Yuichi Inoue
- Japan Somnology Center; Neuropsychiatric Research Institute; Tokyo Japan
- Department of Somnology; Tokyo Medical University; Tokyo Japan
| | - Wolfgang Oertel
- Department of Neurology; Philipps-Universität Marburg; Marburg Germany
| | - Aaro V. Salminen
- Institute of Neurogenomics; Helmholtz Zentrum München; Munich Germany
- Department of Neurology; Philipps-Universität Marburg; Marburg Germany
| | - John W. Winkelman
- Harvard Medical School; Boston Massachusetts USA
- Departments of Psychiatry and Neurology; Massachusetts General Hospital; Boston Massachusetts USA
| | - Claudia Trenkwalder
- Department of Neurosurgery; University Medical Center; Goettingen Germany
- Paracelsus-Elena Hospital; Kassel Germany
| | - Cristina Sampaio
- CHDI Foundation, Princeton, Princeton, NJ, USA, and the Instituto de Medicina Molecular; University of Lisbon; Lisbon Portugal
| |
Collapse
|
10
|
Schormair B, Zhao C, Bell S, Tilch E, Salminen AV, Pütz B, Dauvilliers Y, Stefani A, Högl B, Poewe W, Kemlink D, Sonka K, Bachmann CG, Paulus W, Trenkwalder C, Oertel WH, Hornyak M, Teder-Laving M, Metspalu A, Hadjigeorgiou GM, Polo O, Fietze I, Ross OA, Wszolek Z, Butterworth AS, Soranzo N, Ouwehand WH, Roberts DJ, Danesh J, Allen RP, Earley CJ, Ondo WG, Xiong L, Montplaisir J, Gan-Or Z, Perola M, Vodicka P, Dina C, Franke A, Tittmann L, Stewart AFR, Shah SH, Gieger C, Peters A, Rouleau GA, Berger K, Oexle K, Di Angelantonio E, Hinds DA, Müller-Myhsok B, Winkelmann J. Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis. Lancet Neurol 2017; 16:898-907. [PMID: 29029846 PMCID: PMC5755468 DOI: 10.1016/s1474-4422(17)30327-7] [Citation(s) in RCA: 143] [Impact Index Per Article: 20.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2017] [Revised: 08/10/2017] [Accepted: 08/17/2017] [Indexed: 02/02/2023]
Abstract
BACKGROUND Restless legs syndrome is a prevalent chronic neurological disorder with potentially severe mental and physical health consequences. Clearer understanding of the underlying pathophysiology is needed to improve treatment options. We did a meta-analysis of genome-wide association studies (GWASs) to identify potential molecular targets. METHODS In the discovery stage, we combined three GWAS datasets (EU-RLS GENE, INTERVAL, and 23andMe) with diagnosis data collected from 2003 to 2017, in face-to-face interviews or via questionnaires, and involving 15 126 cases and 95 725 controls of European ancestry. We identified common variants by fixed-effect inverse-variance meta-analysis. Significant genome-wide signals (p≤5 × 10-8) were tested for replication in an independent GWAS of 30 770 cases and 286 913 controls, followed by a joint analysis of the discovery and replication stages. We did gene annotation, pathway, and gene-set-enrichment analyses and studied the genetic correlations between restless legs syndrome and traits of interest. FINDINGS We identified and replicated 13 new risk loci for restless legs syndrome and confirmed the previously identified six risk loci. MEIS1 was confirmed as the strongest genetic risk factor for restless legs syndrome (odds ratio 1·92, 95% CI 1·85-1·99). Gene prioritisation, enrichment, and genetic correlation analyses showed that identified pathways were related to neurodevelopment and highlighted genes linked to axon guidance (associated with SEMA6D), synapse formation (NTNG1), and neuronal specification (HOXB cluster family and MYT1). INTERPRETATION Identification of new candidate genes and associated pathways will inform future functional research. Advances in understanding of the molecular mechanisms that underlie restless legs syndrome could lead to new treatment options. We focused on common variants; thus, additional studies are needed to dissect the roles of rare and structural variations. FUNDING Deutsche Forschungsgemeinschaft, Helmholtz Zentrum München-Deutsches Forschungszentrum für Gesundheit und Umwelt, National Research Institutions, NHS Blood and Transplant, National Institute for Health Research, British Heart Foundation, European Commission, European Research Council, National Institutes of Health, National Institute of Neurological Disorders and Stroke, NIH Research Cambridge Biomedical Research Centre, and UK Medical Research Council.
Collapse
Affiliation(s)
- Barbara Schormair
- Institute of Neurogenomics, Helmholtz Zentrum München, German Research Centre for Environmental Health, Neuherberg, Germany
| | - Chen Zhao
- Institute of Neurogenomics, Helmholtz Zentrum München, German Research Centre for Environmental Health, Neuherberg, Germany
| | - Steven Bell
- National Institute for Health Research Blood and Transplant Unit in Donor Health and Genomics at the University of Cambridge, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK; MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK; National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK
| | - Erik Tilch
- Institute of Neurogenomics, Helmholtz Zentrum München, German Research Centre for Environmental Health, Neuherberg, Germany
| | - Aaro V Salminen
- Institute of Neurogenomics, Helmholtz Zentrum München, German Research Centre for Environmental Health, Neuherberg, Germany
| | - Benno Pütz
- Max Planck Institute of Psychiatry, Munich, Germany
| | - Yves Dauvilliers
- Sleep-Wake Disorders Centre, Department of Neurology, Hôpital Gui-de-Chauliac, INSERM U1061, CHU Montpellier, France
| | - Ambra Stefani
- Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
| | - Birgit Högl
- Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
| | - Werner Poewe
- Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
| | - David Kemlink
- Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic
| | - Karel Sonka
- Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic
| | | | - Walter Paulus
- Department of Clinical Neurophysiology, University Medical Centre, Georg August University Göttingen, Göttingen, Germany
| | - Claudia Trenkwalder
- Clinic for Neurosurgery, University Medical Centre, Georg August University Göttingen, Göttingen, Germany; Paracelsus-Elena Hospital, Centre of Parkinsonism and Movement Disorders, Kassel, Germany
| | - Wolfgang H Oertel
- Institute of Neurogenomics, Helmholtz Zentrum München, German Research Centre for Environmental Health, Neuherberg, Germany; Department of Neurology, Philipps University Marburg, Marburg, Germany
| | - Magdolna Hornyak
- Department of Neurology, University of Ulm, Ulm, Germany; Neuropsychiatry Centre Erding/München, Erding, Germany
| | - Maris Teder-Laving
- Estonian Genome Centre, University of Tartu and Estonian Biocentre, Tartu, Estonia
| | - Andres Metspalu
- Estonian Genome Centre, University of Tartu and Estonian Biocentre, Tartu, Estonia
| | - Georgios M Hadjigeorgiou
- Laboratory of Neurogenetics, Department of Neurology, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, Larissa, Greece
| | - Olli Polo
- Unesta Research Centre, Tampere, Finland; Department of Pulmonary Diseases, Tampere University Hospital, Tampere, Finland
| | - Ingo Fietze
- Department of Cardiology and Angiology, Centre of Sleep Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Owen A Ross
- Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA
| | | | - Adam S Butterworth
- National Institute for Health Research Blood and Transplant Unit in Donor Health and Genomics at the University of Cambridge, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK; MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK; National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK; British Heart Foundation Centre of Excellence, Division of Cardiovascular Medicine, Addenbrooke's Hospital, Cambridge, UK
| | - Nicole Soranzo
- National Institute for Health Research Blood and Transplant Unit in Donor Health and Genomics at the University of Cambridge, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK; Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK; Department of Human Genetics, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK
| | - Willem H Ouwehand
- National Institute for Health Research Blood and Transplant Unit in Donor Health and Genomics at the University of Cambridge, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK; Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK; NHS Blood and Transplant, Cambridge, UK; British Heart Foundation Centre of Excellence, Division of Cardiovascular Medicine, Addenbrooke's Hospital, Cambridge, UK; Department of Human Genetics, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK
| | - David J Roberts
- NHS Blood and Transplant, Oxford, UK; Radcliffe Department of Medicine, BRC Haematology Theme and NHS Blood and Transplant, John Radcliffe Hospital, Headington, Oxford, UK; Department of Haematology and BRC Haematology Theme, Churchill Hospital, Oxford, UK
| | - John Danesh
- National Institute for Health Research Blood and Transplant Unit in Donor Health and Genomics at the University of Cambridge, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK; MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK; National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK; British Heart Foundation Centre of Excellence, Division of Cardiovascular Medicine, Addenbrooke's Hospital, Cambridge, UK; Department of Human Genetics, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK
| | - Richard P Allen
- Center for Restless Legs Study, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA
| | - Christopher J Earley
- Center for Restless Legs Study, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA
| | - William G Ondo
- Department of Neurology, Methodist Neurological Institute, Houston, TX, USA
| | - Lan Xiong
- Laboratoire de Neurogénétique, Centre de Recherche, Institut Universitaire en Santé Mentale de Montréal, Montréal, QC, Canada; Département de Psychiatrie, Université de Montréal, Montréal, QC, Canada; Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada
| | - Jacques Montplaisir
- Département de Psychiatrie, Université de Montréal, Montréal, QC, Canada; Hôpital du Sacré-Coeur de Montréal, 67120, Center for Advanced Research in Sleep Medicine, Montréal, QC, Canada
| | - Ziv Gan-Or
- Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada; Montreal Neurological Institute, McGill University, Montréal, QC, Canada
| | - Markus Perola
- Department of Health, National Institute for Health and Welfare, Helsinki, Finland; Institute of Molecular Medicine FIMM, University of Helsinki, Helsinki, Finland
| | - Pavel Vodicka
- Department of Molecular Biology of Cancer, Institute of Experimental Medicine, Academy of Science of Czech Republic, Prague, Czech Republic; Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic
| | - Christian Dina
- Inserm UMR1087, CNRS UMR 6291, Institut du Thorax, Nantes, France; Centre Hospitalier Universitaire (CHU) Nantes, Université de Nantes, France
| | - Andre Franke
- Institute of Clinical Molecular Biology, Kiel University, Kiel, Germany
| | - Lukas Tittmann
- PopGen Biobank and Institute of Epidemiology, Christian Albrechts University Kiel, Kiel, Germany
| | - Alexandre F R Stewart
- John and Jennifer Ruddy Canadian Cardiovascular Genetics Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada
| | - Svati H Shah
- Department of Medicine, Duke University School of Medicine, Durham, NC, USA; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA
| | - Christian Gieger
- Institute of Epidemiology II, Helmholtz Zentrum München, German Research Centre for Environmental Health, Neuherberg, Germany; Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Centre for Environmental Health, Neuherberg, Germany; German Centre for Diabetes Research (DZD), Neuherberg, Germany
| | - Annette Peters
- Institute of Epidemiology II, Helmholtz Zentrum München, German Research Centre for Environmental Health, Neuherberg, Germany; German Centre for Diabetes Research (DZD), Neuherberg, Germany; German Centre for Cardiovascular Disease Research (DZHK), Berlin, Germany
| | - Guy A Rouleau
- Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada; Department of Human Genetics, McGill University, Montréal, QC, Canada; Montreal Neurological Institute, McGill University, Montréal, QC, Canada
| | - Klaus Berger
- Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany
| | - Konrad Oexle
- Institute of Neurogenomics, Helmholtz Zentrum München, German Research Centre for Environmental Health, Neuherberg, Germany
| | - Emanuele Di Angelantonio
- National Institute for Health Research Blood and Transplant Unit in Donor Health and Genomics at the University of Cambridge, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK; MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK; NHS Blood and Transplant, Cambridge, UK; National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK; British Heart Foundation Centre of Excellence, Division of Cardiovascular Medicine, Addenbrooke's Hospital, Cambridge, UK
| | | | - Bertram Müller-Myhsok
- Max Planck Institute of Psychiatry, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany; Institute of Translational Medicine, University of Liverpool, Liverpool, UK
| | - Juliane Winkelmann
- Institute of Neurogenomics, Helmholtz Zentrum München, German Research Centre for Environmental Health, Neuherberg, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany; Institute of Human Genetics, Technische Universität München, Munich, Germany; Neurologische Klinik und Poliklinik, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany.
| |
Collapse
|
11
|
Salminen AV, Schormair B, Flachskamm C, Torres M, Müller-Myhsok B, Kimura M, Winkelmann J. Sleep disturbance by pramipexole is modified by Meis1 in mice. J Sleep Res 2017; 27:e12557. [DOI: 10.1111/jsr.12557] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2017] [Accepted: 04/07/2017] [Indexed: 10/19/2022]
Affiliation(s)
- Aaro V. Salminen
- Institute of Neurogenomics; Helmholtz Zentrum München; Munich Germany
| | - Barbara Schormair
- Institute of Neurogenomics; Helmholtz Zentrum München; Munich Germany
| | | | - Miguel Torres
- Department of Cardiovascular Development and Repair; Centro Nacional de Investigaciones Cardiovasculares (CNIC); Madrid Spain
| | - Bertram Müller-Myhsok
- Max Planck Institute of Psychiatry; Munich Germany
- Institute of Translational Medicine; University of Liverpool; Liverpool UK
- Munich Cluster for Systems Neurology (SyNergy); Munich Germany
| | | | - Juliane Winkelmann
- Institute of Neurogenomics; Helmholtz Zentrum München; Munich Germany
- Munich Cluster for Systems Neurology (SyNergy); Munich Germany
- Institute of Human Genetics; Klinikum Rechts der Isar; Technische Universität München; Munich Germany
- Neurologic Clinic; Klinikum rechts der Isar; Technische Universität München; Munich Germany
| |
Collapse
|
12
|
Salminen AV, Garrett L, Schormair B, Rozman J, Giesert F, Niedermeier KM, Becker L, Rathkolb B, Rácz I, Klingenspor M, Klopstock T, Wolf E, Zimmer A, Gailus-Durner V, Torres M, Fuchs H, Hrabě de Angelis M, Wurst W, Hölter SM, Winkelmann J. Meis1: effects on motor phenotypes and the sensorimotor system in mice. Dis Model Mech 2017. [PMID: 28645892 PMCID: PMC5560065 DOI: 10.1242/dmm.030080] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
MEIS1 encodes a developmental transcription factor and has been linked to restless legs syndrome (RLS) in genome-wide association studies. RLS is a movement disorder leading to severe sleep reduction and has a substantial impact on the quality of life of patients. In genome-wide association studies, MEIS1 has consistently been the gene with the highest effect size and functional studies suggest a disease-relevant downregulation. Therefore, haploinsufficiency of Meis1 could be the system with the most potential for modeling RLS in animals. We used heterozygous Meis1-knockout mice to study the effects of Meis1 haploinsufficiency on mouse behavioral and neurological phenotypes, and to relate the findings to human RLS. We exposed the Meis1-deficient mice to assays of motor, sensorimotor and cognitive ability, and assessed the effect of a dopaminergic receptor 2/3 agonist commonly used in the treatment of RLS. The mutant mice showed a pattern of circadian hyperactivity, which is compatible with human RLS. Moreover, we discovered a replicable prepulse inhibition (PPI) deficit in the Meis1-deficient animals. In addition, these mice were hyposensitive to the PPI-reducing effect of the dopaminergic receptor agonist, highlighting a role of Meis1 in the dopaminergic system. Other reported phenotypes include enhanced social recognition at an older age that was not related to alterations in adult olfactory bulb neurogenesis previously shown to be implicated in this behavior. In conclusion, the Meis1-deficient mice fulfill some of the hallmarks of an RLS animal model, and revealed the role of Meis1 in sensorimotor gating and in the dopaminergic systems modulating it. Summary: Loss of Meis1 results in motor restlessness in mice, a phenotype resembling human restless legs syndrome, as well as altered sensorimotor gating and improved social discrimination memory.
Collapse
Affiliation(s)
- Aaro V Salminen
- Institute of Neurogenomics, Helmholtz Zentrum München, 85764 Neuherberg, Germany
| | - Lillian Garrett
- Institute of Developmental Genetics, Helmholtz Zentrum München, 85764 Neuherberg, Germany.,German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, 85764 Neuherberg, Germany
| | - Barbara Schormair
- Institute of Neurogenomics, Helmholtz Zentrum München, 85764 Neuherberg, Germany
| | - Jan Rozman
- German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, 85764 Neuherberg, Germany.,German Center for Diabetes Research (DZD), 85764 Neuherberg, Germany
| | - Florian Giesert
- Institute of Developmental Genetics, Helmholtz Zentrum München, 85764 Neuherberg, Germany
| | - Kristina M Niedermeier
- Institute of Developmental Genetics, Helmholtz Zentrum München, 85764 Neuherberg, Germany
| | - Lore Becker
- German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, 85764 Neuherberg, Germany
| | - Birgit Rathkolb
- German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, 85764 Neuherberg, Germany.,German Center for Diabetes Research (DZD), 85764 Neuherberg, Germany.,Institute of Molecular Animal Breeding and Biotechnology, Gene Center, Ludwig-Maximilians-University München, 81377 Munich, Germany
| | - Ildikó Rácz
- German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, 85764 Neuherberg, Germany.,Institute of Molecular Psychiatry, Medical Faculty, University of Bonn, 53127 Bonn, Germany
| | | | - Martin Klingenspor
- Chair of Molecular Nutritional Medicine, Technical University Munich, EKFZ - Else Kröner Fresenius Center for Nutritional Medicine, Gregor-Mendel-Str. 2, 85350 Freising-Weihenstephan, Germany
| | - Thomas Klopstock
- Department of Neurology, Friedrich-Baur-Institute, Klinikum der Ludwig-Maximilians-Universität München, Ziemssenstr. 1a, 80336 Munich, Germany.,Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE), 81377 Munich, Germany.,Munich Cluster for Systems Neurology (SyNergy), Adolf-Butenandt-Institut, Ludwig-Maximilians-Universität München, 81377 Munich, Germany
| | - Eckhard Wolf
- Institute of Molecular Animal Breeding and Biotechnology, Gene Center, Ludwig-Maximilians-University München, 81377 Munich, Germany
| | - Andreas Zimmer
- Institute of Molecular Psychiatry, Medical Faculty, University of Bonn, 53127 Bonn, Germany
| | - Valérie Gailus-Durner
- German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, 85764 Neuherberg, Germany
| | - Miguel Torres
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain
| | - Helmut Fuchs
- German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, 85764 Neuherberg, Germany
| | - Martin Hrabě de Angelis
- German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, 85764 Neuherberg, Germany.,German Center for Diabetes Research (DZD), 85764 Neuherberg, Germany.,Chair of Experimental Genetics, School of Life Science Weihenstephan, Technische Universität 85354 Freising, Germany
| | - Wolfgang Wurst
- Institute of Developmental Genetics, Helmholtz Zentrum München, 85764 Neuherberg, Germany.,Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE), 81377 Munich, Germany.,Munich Cluster for Systems Neurology (SyNergy), Adolf-Butenandt-Institut, Ludwig-Maximilians-Universität München, 81377 Munich, Germany.,Chair of Developmental Genetics, Faculty of Life and Food Sciences Weihenstephan, Technische Universität München, 85354 Freising, Germany
| | - Sabine M Hölter
- Institute of Developmental Genetics, Helmholtz Zentrum München, 85764 Neuherberg, Germany.,German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, 85764 Neuherberg, Germany
| | - Juliane Winkelmann
- Institute of Neurogenomics, Helmholtz Zentrum München, 85764 Neuherberg, Germany .,Munich Cluster for Systems Neurology (SyNergy), Adolf-Butenandt-Institut, Ludwig-Maximilians-Universität München, 81377 Munich, Germany.,Institute of Human Genetics, Klinikum Rechts der Isar, Technische Universität München, 81675 Munich, Germany.,Neurologic Clinic, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany
| |
Collapse
|
13
|
Rimpilä V, Hosokawa K, Huhtala H, Saaresranta T, Salminen AV, Polo O. Transcutaneous carbon dioxide during sleep-disordered breathing. Respir Physiol Neurobiol 2015; 219:95-102. [PMID: 26474829 DOI: 10.1016/j.resp.2015.10.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2015] [Revised: 09/15/2015] [Accepted: 10/06/2015] [Indexed: 11/30/2022]
Abstract
Respiratory drive is tightly controlled by the carbon dioxide levels. We tested the hypothesis that sequences of sleep apnoea (obstructive, central or mixed), hypopnoea and flow limitation are characterized by different levels of transcutaneous CO2 (PtcCO2). Polygraphic recordings (n=555) from patients with suspected sleep-disordered breathing (SDB) were retrospectively screened to find sequences (5 min or 10 events) of both SDB and steady breathing. Eighty-eight SDB sequences from 44 patients were included and PtcCO2 and SpO2 values were collected. PtcCO2 values during sequences were normalized by setting wakefulness level as 100%. In terms of PtcCO2, apnoea sequences with central component (central (n=7) and mixed (n=3) apnoea) did not differ from wakefulness (102.0% vs 100%, p=0.122) whereas obstructive apnoea (105.8%, p<0.001) and hypopnoea did (105.4%, p<0.001). PtcCO2 during flow limitation was higher than that during any other sequence, including steady breathing (112.2% vs 108.4%, p=0.022). Continuous PtcCO2 monitoring during sleep adds to the understanding of different SDB phenotypes.
Collapse
Affiliation(s)
- Ville Rimpilä
- School of Medicine, University of Tampere, Finland; Unesta Research Center, Tampere, Finland.
| | | | - Heini Huhtala
- School of Health Sciences, University of Tampere, Finland
| | - Tarja Saaresranta
- Division of Medicine, Department of Pulmonary Diseases, Turku University Hospital, and Department of Pulmonary Diseases and Clinical Allergology and Sleep Research Centre, Department of Physiology, University of Turku, Finland
| | - Aaro V Salminen
- School of Medicine, University of Tampere, Finland; Unesta Research Center, Tampere, Finland
| | - Olli Polo
- Unesta Research Center, Tampere, Finland; Department of Respiratory Medicine, University of Tampere and Tampere University Hospital, Tampere, Finland
| |
Collapse
|
14
|
Salminen AV, Rimpilä V, Polo O. Pramipexole alters thermoregulation in restless legs syndrome. J Clin Sleep Med 2014; 10:1325-9. [PMID: 25325594 DOI: 10.5664/jcsm.4290] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2014] [Accepted: 07/17/2014] [Indexed: 12/31/2022]
Abstract
STUDY OBJECTIVES Previous studies have associated restless legs syndrome (RLS) with peripheral hypoxia and impaired thermoregulation in the lower extremities. We performed long-term monitoring of skin temperatures in order to investigate whether these findings could be explained by reduced blood flow to the peripheral tissues. METHODS 96-hour continuous measurements of skin temperature were performed both in the distal and proximal parts of the body of 15 patients with RLS and 14 healthy controls. During the recording, the patients participated in suggested immobilization tests both with and without pramipexole medication. RESULTS We found no baseline differences in distal or proximal skin temperature between patients and controls in daytime or during immobilization. However, pramipexole significantly increased distal skin temperature in the patient group during immobilization (31.1°C vs. 32.9°C, p < 0.05). Daytime temperatures were not affected by therapy or disease status. CONCLUSIONS The data suggest that patients with RLS and healthy controls have similar blood flow to the peripheral skin tissue. Pramipexole, however, alters thermoregulation and the previous studies might have been biased by medication. Dopaminergic medication is a major confounding factor when assessing peripheral phenomena in RLS and should be controlled for in the future studies.
Collapse
Affiliation(s)
- Aaro V Salminen
- University of Tampere, School of Medicine, Tampere, Finland; Unesta Research Centre, Tampere, Finland
| | - Ville Rimpilä
- University of Tampere, School of Medicine, Tampere, Finland; Unesta Research Centre, Tampere, Finland
| | - Olli Polo
- University of Tampere, School of Medicine, Tampere, Finland; Unesta Research Centre, Tampere, Finland; Department of Respiratory Medicine, Tampere University Hospital, Tampere, Finland
| |
Collapse
|
15
|
Abstract
OBJECTIVE A case-control study to measure oxygen and carbon dioxide partial pressures in the legs in order to assess the involvement of peripheral hypoxia or hypercapnia in the pathogenesis of restless legs syndrome (RLS). METHODS RLS severity was assessed with a standard questionnaire. Suggested immobilization tests were performed twice in 15 patients with RLS and 14 healthy controls. Patients with RLS participated in the tests with and without pramipexole medication. During the tests, peripheral oxygen and carbon dioxide partial pressures were measured noninvasively on the skin of the legs and the chest. RESULTS During immobilization, the patients with RLS had lower partial pressure of oxygen in their legs (5.54 vs 7.19 kPa, p < 0.01) but not on the chest (8.75 vs 8.20 kPa, p = 0.355). More severe RLS correlated with high chest-to-foot oxygen gradient (ρ = 0.692, p < 0.01). Carbon dioxide levels did not differ between the groups. Pramipexole corrected the peripheral hypoxia toward the levels observed in the controls (from 5.54 to 6.65 kPa, p < 0.05). CONCLUSIONS Peripheral hypoxia is associated with the appearance of RLS symptoms. Strong correlation with RLS severity suggests a close pathophysiologic link between peripheral hypoxia and the symptoms of RLS. This is further supported by the simultaneous reversal of hypoxia and discomfort by dopaminergic treatment.
Collapse
Affiliation(s)
- Aaro V Salminen
- From the University of Tampere (A.V.S., V.R., O.P.), School of Medicine; Unesta Research Centre (A.V.S., V.R., O.P.), Tampere; and Department of Respiratory Medicine (O.P.), Tampere University Hospital, Finland.
| | - Ville Rimpilä
- From the University of Tampere (A.V.S., V.R., O.P.), School of Medicine; Unesta Research Centre (A.V.S., V.R., O.P.), Tampere; and Department of Respiratory Medicine (O.P.), Tampere University Hospital, Finland
| | - Olli Polo
- From the University of Tampere (A.V.S., V.R., O.P.), School of Medicine; Unesta Research Centre (A.V.S., V.R., O.P.), Tampere; and Department of Respiratory Medicine (O.P.), Tampere University Hospital, Finland
| |
Collapse
|
16
|
Stuani L, Lechaplais C, Salminen AV, Ségurens B, Durot M, Castelli V, Pinet A, Labadie K, Cruveiller S, Weissenbach J, de Berardinis V, Salanoubat M, Perret A. Novel metabolic features in Acinetobacter baylyi ADP1 revealed by a multiomics approach. Metabolomics 2014; 10:1223-1238. [PMID: 25374488 PMCID: PMC4213383 DOI: 10.1007/s11306-014-0662-x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2013] [Accepted: 04/07/2014] [Indexed: 11/26/2022]
Abstract
Expansive knowledge of bacterial metabolism has been gained from genome sequencing output, but the high proportion of genes lacking a proper functional annotation in a given genome still impedes the accurate prediction of the metabolism of a cell. To access to a more global view of the functioning of the soil bacterium Acinetobacter baylyi ADP1, we adopted a multi 'omics' approach. Application of RNA-seq transcriptomics and LC/MS-based metabolomics, along with the systematic phenotyping of the complete collection of single-gene deletion mutants of A. baylyi ADP1 made possible to interrogate on the metabolic perturbations encountered by the bacterium upon a biotic change. Shifting the sole carbon source from succinate to quinate elicited in the cell not only a specific transcriptional response, necessary to catabolize the new carbon source, but also a major reorganization of the transcription pattern. Here, the expression of more than 12 % of the total number of genes was affected, most of them being of unknown function. These perturbations were ultimately reflected in the metabolome, in which the concentration of about 50 % of the LC/MS-detected metabolites was impacted. And the differential regulation of many genes of unknown function is probably related to the synthesis of the numerous unidentified compounds that were present exclusively in quinate-grown cells. Together, these data suggest that A. baylyi ADP1 metabolism involves unsuspected enzymatic reactions that await discovery.
Collapse
Affiliation(s)
- Lucille Stuani
- Direction des Sciences du Vivant, Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Institut de Génomique, Evry, France
- CNRS-UMR8030, Evry, France
- Université d’Evry Val d’Essonne, Evry, France
| | - Christophe Lechaplais
- Direction des Sciences du Vivant, Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Institut de Génomique, Evry, France
- CNRS-UMR8030, Evry, France
- Université d’Evry Val d’Essonne, Evry, France
| | - Aaro V. Salminen
- Direction des Sciences du Vivant, Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Institut de Génomique, Evry, France
- CNRS-UMR8030, Evry, France
- Université d’Evry Val d’Essonne, Evry, France
- Department of Chemistry and Bioengineering, Tampere University of Technology, Korkeakoulunkatu 10, 33720 Tampere, Finland
| | - Béatrice Ségurens
- Direction des Sciences du Vivant, Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Institut de Génomique, Evry, France
- CNRS-UMR8030, Evry, France
- Université d’Evry Val d’Essonne, Evry, France
| | - Maxime Durot
- Direction des Sciences du Vivant, Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Institut de Génomique, Evry, France
- CNRS-UMR8030, Evry, France
- Université d’Evry Val d’Essonne, Evry, France
| | - Vanina Castelli
- Direction des Sciences du Vivant, Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Institut de Génomique, Evry, France
- CNRS-UMR8030, Evry, France
- Université d’Evry Val d’Essonne, Evry, France
| | - Agnès Pinet
- Direction des Sciences du Vivant, Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Institut de Génomique, Evry, France
- CNRS-UMR8030, Evry, France
- Université d’Evry Val d’Essonne, Evry, France
| | - Karine Labadie
- Direction des Sciences du Vivant, Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Institut de Génomique, Evry, France
- CNRS-UMR8030, Evry, France
- Université d’Evry Val d’Essonne, Evry, France
| | - Stéphane Cruveiller
- Direction des Sciences du Vivant, Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Institut de Génomique, Evry, France
- CNRS-UMR8030, Evry, France
- Université d’Evry Val d’Essonne, Evry, France
| | - Jean Weissenbach
- Direction des Sciences du Vivant, Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Institut de Génomique, Evry, France
- CNRS-UMR8030, Evry, France
- Université d’Evry Val d’Essonne, Evry, France
| | - Véronique de Berardinis
- Direction des Sciences du Vivant, Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Institut de Génomique, Evry, France
- CNRS-UMR8030, Evry, France
- Université d’Evry Val d’Essonne, Evry, France
| | - Marcel Salanoubat
- Direction des Sciences du Vivant, Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Institut de Génomique, Evry, France
- CNRS-UMR8030, Evry, France
- Université d’Evry Val d’Essonne, Evry, France
| | - Alain Perret
- Direction des Sciences du Vivant, Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Institut de Génomique, Evry, France
- CNRS-UMR8030, Evry, France
- Université d’Evry Val d’Essonne, Evry, France
| |
Collapse
|
17
|
Salminen AV, Manconi M, Rimpilä V, Luoto TM, Koskinen E, Ferri R, Ohman J, Polo O. Disconnection between periodic leg movements and cortical arousals in spinal cord injury. J Clin Sleep Med 2013; 9:1207-9. [PMID: 24235905 DOI: 10.5664/jcsm.3174] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
OBJECTIVE In this study we examine the temporal connection between periodic leg movements (PLMs) and cortical arousals, as well as the treatment effect of pramipexole, in a clinical case with spinal cord lesion. METHODS A patient with complete cervical spinal cord injury and PLMs during sleep underwent two baseline sleep recordings, one recording with dopaminergic treatment, and one recording with adaptive servoventilation. RESULTS The PLMs were temporally dissociated from cortical arousals as well as from respiratory or heart rate events. PLMs were suppressed by pramipexole and persisted after treatment of apnea. CONCLUSION The disconnection of PLMs from arousals supports a spinal generator or peripheral trigger mechanism for PLMs. The suppression of movements by a dopamine agonist suggests that its site of action is caudal to the cervical lesion and outside of the brain. Our observation provides significant new knowledge about the pathogenesis of PLMs and warrants studies in larger populations.
Collapse
Affiliation(s)
- Aaro V Salminen
- University of Tampere, School of Medicine, Tampere, Finland ; Unesta Research Centre, Tampere, Finland
| | | | | | | | | | | | | | | |
Collapse
|